Mahmood Usama, Levy Lawrence B, Nguyen Paul L, Lee Andrew K, Kuban Deborah A, Hoffman Karen E
Departments of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas, and Brigham and Women's Hospital, Harvard Medical School (PLN), Boston, Massachusetts.
Departments of Radiation Oncology, M.D. Anderson Cancer Center, Houston, Texas, and Brigham and Women's Hospital, Harvard Medical School (PLN), Boston, Massachusetts.
J Urol. 2014 Dec;192(6):1650-6. doi: 10.1016/j.juro.2014.06.017. Epub 2014 Jun 12.
SEER recently released patient Gleason scores at biopsy/transurethral resection of the prostate. For the first time this permits accurate assessment of prostate cancer presentation and treatment according to clinical factors at diagnosis.
We used the SEER database to identify men diagnosed with localized prostate cancer in 2010 who were assigned NCCN(®) risk based on clinical factors. We identified sociodemographic factors associated with high risk disease and analyzed the impact of these factors along with NCCN risk on local treatment.
Of the 42,403 men identified disease was high, intermediate and low risk in 38%, 40% and 22%, respectively. On multivariate analysis patients who were older, nonwhite, unmarried or living in a county with a higher poverty rate were more likely to be diagnosed with high risk disease (each p <0.05). Of the 38,634 men in whom prostate cancer was the first malignancy 23% underwent no local treatment, 40% were treated with prostatectomy, 36% received radiation therapy and 1% underwent local tumor destruction, predominantly cryotherapy. On multivariate analysis patients who were older, black, unmarried or living in a county with a higher poverty rate, or who had low risk disease were less likely to receive local treatment (each p <0.05).
Our analysis provides information on the current clinical presentation and treatment of localized prostate cancer in the United States. Nonwhite and older men living in a county with a higher poverty rate were more likely to be diagnosed with high risk disease and less likely to receive local treatment.
监测、流行病学与最终结果(SEER)项目最近公布了前列腺活检/经尿道前列腺切除术患者的 Gleason 评分。这首次使得能够根据诊断时的临床因素对前列腺癌的表现和治疗进行准确评估。
我们使用 SEER 数据库来识别 2010 年被诊断为局限性前列腺癌且根据临床因素被指定为美国国立综合癌症网络(NCCN)风险分级的男性。我们确定了与高危疾病相关的社会人口统计学因素,并分析了这些因素以及 NCCN 风险分级对局部治疗的影响。
在识别出的 42403 名男性中,疾病为高危、中危和低危的分别占 38%、40%和 22%。多因素分析显示,年龄较大、非白人、未婚或生活在贫困率较高县的患者更有可能被诊断为高危疾病(各 p<0.05)。在 38634 名前列腺癌为首发恶性肿瘤的男性中,23%未接受局部治疗,40%接受了前列腺切除术,36%接受了放射治疗,1%接受了局部肿瘤破坏治疗,主要是冷冻治疗。多因素分析显示,年龄较大、黑人、未婚或生活在贫困率较高县的患者,或患有低危疾病的患者接受局部治疗的可能性较小(各 p<0.05)。
我们的分析提供了关于美国局限性前列腺癌当前临床表现和治疗的信息。生活在贫困率较高县的非白人和老年男性更有可能被诊断为高危疾病,且接受局部治疗的可能性较小。